Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in

Simon Lebek1,2,3, Xurde M Caravia1,2, Francesco Chemello1,2

  • 1Department of Molecular Biology (S.L., X.M.C., F.C., W.T., J.R.M., N.L., R.B.-D., E.N.O.), University of Texas Southwestern Medical Center, Dallas.

Circulation
|September 15, 2023
PubMed

Insights

Gene editing to block CaMKIIδ overactivation significantly improved cardiac function and survival in a mouse model of heart failure. This approach shows promise for treating human cardiac diseases by targeting a key enzyme in cardiac dysfunction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Gene Editing Technologies

Background:

  • Cardiovascular diseases are a leading cause of death globally, necessitating novel therapeutic strategies.
  • Overactivation of the cardiac enzyme Ca2+/calmodulin-dependent protein kinase IIδ (CaMKIIδ) is a key factor in various heart disorders.

Purpose of the Study:

  • To develop a gene-editing therapy for heart failure by targeting the autophosphorylation site of CaMKIIδ.
  • To assess the efficacy and safety of CRISPR-Cas9 adenine base editing in a mouse model of heart failure and in human cells.

Main Methods:

  • CRISPR-Cas9 adenine base editing was used to create a phospho-resistant CaMKIIδ mutation in mice.
  • Mice underwent transverse aortic constriction to induce heart failure; cardiac function, gene expression, apoptosis, and fibrosis were evaluated.
  • Human induced pluripotent stem cells were edited to target the homologous CaMKIIδ site, with specificity assessed via deep amplicon sequencing.

Main Results:

  • Gene-edited mice exhibited significantly reduced mortality (11% vs. 65%) and improved cardiac function post-heart failure induction compared to wild-type mice.
  • CaMKIIδ-edited mice were protected against heart failure-induced changes in gene expression, apoptosis, and fibrosis.
  • Edited human cells and cardiomyocytes showed protection against Ca2+ dysregulation and arrhythmias under stress, with high editing specificity for CaMKIIδ.

Conclusions:

  • Ablating CaMKIIδ autophosphorylation via adenine base editing offers a potential therapeutic strategy for human cardiac diseases.
  • The high specificity of the gene editing tool for CaMKIIδ is a critical safety feature for potential clinical translation.
Abstract